MONET1-MOtesanib NSCLC Efficacy and Tolerability Study

PHASE3TerminatedINTERVENTIONAL
Enrollment

1,450

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

March 31, 2011

Study Completion Date

August 31, 2013

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

AMG 706

125 mg QD orally every day

DRUG

placebo

125 mg QD orally every day

DRUG

paclitaxel

200mg/m2 on day 1 of each 3 week cycle +/- 3 days for a max of 6 cycles

DRUG

carboplatin

AUC of 600mg/mL x min by Calvert formula on day 1 of each 3 week cycle +/- 3 days for a max of 6 cycles

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Takeda

INDUSTRY

lead

Amgen

INDUSTRY